Wilfried Dinh/LinkedIn
Aug 18, 2026, 12:59
Wilfried Dinh: Why Targeting IL-6 Failed in Heart Disease
Wilfried Dinh, Senior Clinical Program Leader at Boehringer Ingelheim, shared a post on LinkedIn:
“Interesting viewpoint:
Why did IL-6 inhibition fail in cardiovascular disease?
ZEUS provides a sobering translational lesson:
- 6,376 patients with ASCVD, CKD and inflammation
- Ziltivekimab vs placebo
- Strong inflammatory biomarker suppression
- MACE: HR 0.99 (95% CI 0.88 – 1.11)
- Signal for more serious infections
Takeaway: Target engagement is not clinical validation.
CRP reduction does not necessarily translate into plaque modification or fewer cardiovascular events.
Perhaps the bigger lesson is for genetics-guided drug development: causal biology is not equal to guaranteed therapeutic efficacy.
Disclaimer: Views are my own as a physician or researcher, not those of my employer or affiliated organizations.
For scientific discussion only.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026